

Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-503347DA-D9AD-494C-85D6-63CB06354654_1_en-US
DOI: https://doi.org/10.31003/USPNF_M1781_01_01
DOI Ref: 6lxq6

© 2025 USPC
Do not distribute

Amiodarone Hydrochloride Compounded Oral Suspension

DEFINITION

Amiodarone Hydrochloride Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of amiodarone hydrochloride ($C_{25}H_{29}I_2NO_3 \cdot HCl$).

Prepare Amiodarone Hydrochloride Compounded Oral Suspension 5 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Amiodarone Hydrochloride tablets ^a equivalent to	600 mg of amiodarone hydrochloride
Vehicle: a 1:1 mixture of Ora-Sweet ^b (regular or sugar-free) and Ora-Plus, ^b a sufficient quantity to make	120 mL

^a Cordarone 200-mg tablets, Wyeth-Ayerst Laboratories, Philadelphia, PA.

^b Paddock Laboratories, Minneapolis, MN.

Calculate the required quantity of each ingredient for the total amount to be prepared. Place the required number of *Amiodarone Hydrochloride tablets* in a suitable mortar and comminute to a fine powder with a pestle. Adjust the pH of the *Vehicle* to 6.5 ± 0.5 with a sodium bicarbonate 50-mg/mL solution prepared in Purified Water. Add the *Vehicle* in small portions and triturate to make a smooth paste. Add increasing volumes of the *Vehicle* to make an amiodarone hydrochloride liquid that is pourable. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add enough of the *Vehicle* to bring to final volume and mix well.

ASSAY

PROCEDURE

Mobile phase: Methanol, water, and 50 mM monobasic ammonium phosphate (0.5:0.5:99)

Standard solution: 2.5 mg/mL of [USP Amiodarone Hydrochloride RS](#) in *Mobile phase*

Sample solution: Shake thoroughly by hand each bottle of the Oral Suspension. Prepare 2.5 mg/mL of amiodarone hydrochloride from Oral Suspension and *Mobile phase*.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 25-cm; 10-μm packing L1

Flow rate: 1.5 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for amiodarone is about 3.6 min.]

Suitability requirements

Relative standard deviation: NMT 2.1% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of amiodarone hydrochloride ($C_{25}H_{29}I_2NO_3 \cdot HCl$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Amiodarone Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of amiodarone hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **pH** (791): 5.8–6.8

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator or at controlled room temperature.
- **BEYOND-USE DATE:** NMT 90 days after the date on which it was compounded when stored in a refrigerator; NMT 30 days when stored at controlled room temperature
- **LABELING:** Label it to state that it is to be well shaken before use and to state the *Beyond-Use Date*.
- **USP REFERENCE STANDARDS** (11).
[USP Amiodarone Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
AMIODARONE HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(5)

Current DocID: GUID-503347DA-D9AD-494C-85D6-63CB06354654_1_en-US

DOI: https://doi.org/10.31003/USPNE_M1781_01_01

DOI ref: [6lxq6](#)